Anti-IL-5 and hypereosinophilic syndromes

SUTTON, S; ASSAAD, A; ROTHENBERG, M

doi:10.1016/j.clim.2005.02.006

Cited by 40Eosinophilic Disorders and SyndromesAsthma and respiratory diseasesImmunodeficiency and Autoimmune Disorders

Anti-IL-5 and hypereosinophilic syndromes

SUTTON, S, ASSAAD, A, ROTHENBERG, M·2005·Clinical Immunology

DOI 10.1016/j.clim.2005.02.006

Open this paper in CoChat — free account

Abstract

Hypereosinophilic syndromes represent a heterogeneous group of disorders characterized by peripheral eosinophilia and end-organ damage associated with eosinophil infiltrations. In many instances, the eosinophilia is refractory to standard therapies and clinicians rely on potentially toxic alternatives. This group of disorders has recently gained attention with the description of patients that harbor a genetic rearrangement that produces a constitutively active tyrosine kinase, often responsive to anti-tyrosine kinase therapy. In addition, the recent expansion in our understanding of the mechanisms by which eosinophils develop and become activated, involving the cytokine interleukin-5 (IL-5), has led to advances in therapeutic options. A new therapy currently in clinical trials is the humanized monoclonal antibody against IL-5. This review will discuss the etiology, classification, and treatment options for the hypereosinophilic syndromes, with particular emphasis on anti-interleukin-5 therapy.

Integrity signals

Registry

Crossref · 10.1016/j.clim.2005.02.006

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

IL-5 is one of the main pathogenesis players of hypereosinophilic syndrome.
“Consequently, IL-5 is one of the main pathogenesis players of hypereosinophilic syndrome (HES).125”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [125]

World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079 · see citing works
World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,633 · see citing works
Predominant TH2-like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma
Robinson, D. S., Hamid, Q. A., Ying, S., Tsicopoulos, A., Barkans, J. R., Bentley, A. M., Corrigan, C. J., Durham, S. R., & Kay, A. B. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260504 · Cited by 2,767 · see citing works
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response
Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A., Cowley, H., Chung, K. F., Djukanović, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,810 · see citing works
A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
Cools, J., DeAngelo, D. J., Gotlib, J. R., Stover, E. H., Legare, R. D., Cortes, J. E., Kutok, J. L., Clark, J., Galinsky, I. A., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,704 · see citing works
The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.
Chusid, M. J., Dale, D. C., West, B. C., & Wolff, S. M. (1975) · PubMed · Cited by 1,233 · see citing works
Pathology and genetics
Eble, J. N. (2004) · Medical Entomology and Zoology · Cited by 1,124 · see citing works
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Núñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,107 · see citing works
The idiopathic hypereosinophilic syndrome
Weller, P., & Bubley, G. (1994) · Blood · doi:10.1182/blood.v83.10.2759.2759 · Cited by 929 · see citing works
Interleukin-5, eosinophils, and disease
Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.3101 · Cited by 860 · see citing works
Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics
Flood-Page, P. T., Menzies-Gow, A. N., Phipps, S., Sun, Y., Wangoo, A., Ludwig, M. S., Barnes, N. C., Robinson, D. S., & Kay, A. B. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17974 · Cited by 843 · see citing works
The Idiopathic Hypereosinophilic Syndrome: Clinical, Pathophysiologic, and Therapeutic Considerations
FAUCI, A. S., HARLEY, J. B., ROBERTS, W. C., FERRANS, V. J., GRALNICK, H. R., & BJORNSON, B. H. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-1-78 · Cited by 823 · see citing works
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J. H., Ashman, L. K., & Kanayama, Y. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116761 · Cited by 814 · see citing works
Eosinophil's Role Remains Uncertain as Anti–Interleukin-5 only Partially Depletes Numbers in Asthmatic Airway
Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B., & Robinson, D. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-789oc · Cited by 808 · see citing works
Expression cloning of the human IL-3 receptor cDNA reveals a shared β subunit for the human IL-3 and GM-CSF receptors
Kitamura, T., Sato, N., Arai, K., & Miyajima, A. (1991) · Cell · doi:10.1016/0092-8674(91)90039-2 · Cited by 594 · see citing works
A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific α chain and a β chain shared with the receptor for GM-CSF
Tavernier, J. H., Devos, R., Cornelis, S., Tuypens, T., der Heyden, J. V., Fiers, W., & Plaetinck, G. (1991) · Cell · doi:10.1016/0092-8674(91)90040-6 · Cited by 573 · see citing works
Effect of SCH55700, a Humanized Anti-Human Interleukin-5 Antibody, in Severe Persistent Asthma: A Pilot Study
KIPS, J. C., O'Connor, B. J., Langley, S. J., Woodcock, A. A., Kerstjens, H. A. M., Postma, D. S., Danzig, M., Cuss, F. M., & PAUWELS, R. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-525oc · Cited by 494 · see citing works
Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation
Lamkhioued, B., RENZI, P. M., Abi-Younes, S., Garcia-Zepada, E. A., Allakhverdi, Z., Ghaffar, O., Rothenberg, M. E., Luster, A. D., & Hamid, Q. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.9.4593 · Cited by 409 · see citing works
Self-citation
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
Pardanani, A. D., Ketterling, R. P., Brockman, S. R., Flynn, H. C., Paternoster, S. F., Shearer, B. M., Reeder, T. L., Li, C., Cross, N. C. P., Cools, J., et al. (2003) · Blood · doi:10.1182/blood-2003-05-1627 · Cited by 388 · see citing works
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness
Klion, A. D., Noël, P., Akin, C., Law, M. A., Gilliland, D. G., Cools, J., Metcalfe, D. D., & Nutman, T. B. (2003) · Blood · doi:10.1182/blood-2003-01-0006 · Cited by 385 · see citing works
Anti–interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes
Garrett, J. K., Jameson, S. C., Thomson, B. G., Collins, M. H., Wagoner, L. E., Freese, D. K., Beck, L. A., Boyce, J. A., Filipovich, A. H., Villanueva, J. M., et al. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.10.049 · Cited by 362 · see citing works
Self-citation
Clonal Proliferation of Type 2 Helper T Cells in a Man with the Hypereosinophilic Syndrome
Cogan, E., Schandené, L., Crusiaux, A., Cochaux, P., Velu, T. J., & Goldman, M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199402243300804 · Cited by 305 · see citing works
Treatment of hypereosinophilic syndrome with imatinib mesilate
Gleich, G. J., Leiferman, K. M., Pardanani, A. D., Tefferi, A., & Butterfield, J. H. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08505-7 · Cited by 303 · see citing works
Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis
Plötz, S. G., Simon, H., Darsow, U. G., Simon, D., Vassina, E. M., Yousefi, S., Hein, R., Smith, T., Behrendt, H., & Ring, J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031261 · Cited by 257 · see citing works
Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys
Hart, T. K., Cook, R. M., Zia‐Amirhosseini, P., Minthorn, E. A., Sellers, T. S., Maleeff, B. E., Eustis, S. L., Schwartz, L. W., Tsui, P., Appelbaum, E. R., et al. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.116576 · Cited by 236 · see citing works
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
Pardanani, A. D., Reeder, T. L., Porrata, L. F., Li, C., Tazelaar, H. D., Baxter, E. J., Witzig, T. E., Cross, N. C. P., & Tefferi, A. (2003) · Blood · doi:10.1182/blood-2002-10-3103 · Cited by 221 · see citing works
The eosinophilias, including the idiopathic hypereosinophilic syndrome
Brito‐Babapulle, F. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04195.x · Cited by 208 · see citing works
Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome
Roufosse, F. E., Schandené, L., Sibille, C., Willard-Gallo, K. E., Kennès, B., Efira, A., Goldman, M., & Cogan, E. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02097.x · Cited by 182 · see citing works
Safety and efficacy of the monoclonal anti–interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome
Klion, A. D., Law, M. A., Noël, P., Kim, Y., Haverty, T. P., & Nutman, T. B. (2003) · Blood · doi:10.1182/blood-2003-10-3620 · Cited by 162 · see citing works
Differential Regulation of Human Eosinophil IL-3, IL-5, and GM-CSF Receptor α-Chain Expression by Cytokines: IL-3, IL-5, and GM-CSF Down-Regulate IL-5 Receptor α Expression with Loss of IL-5 Responsiveness, but Up-Regulate IL-3 Receptor α Expression
Gregory, B., Kirchem, A., Phipps, S., Gevaert, P., Pridgeon, C., Rankin, S. M., & Robinson, D. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.11.5359 · Cited by 130 · see citing works
Familial Eosinophilia Maps to the Cytokine Gene Cluster on Human Chromosomal Region 5q31-q33
Rioux, J. D., Stone, V., Daly, M. J., Cargill, M., Green, T. J., Nguyen, H., Nutman, T. B., Zimmerman, P. A., Tucker, M. A., Hudson, T. J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/302053 · Cited by 124 · see citing works
Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib
Wilkinson, K., Velloso, E. D. R. P., Lopes, L. F., Lee, C., Aster, J. C., Shipp, M. A., & Aguiar, R. C. T. (2003) · Blood · doi:10.1182/blood-2003-04-1150 · Cited by 116 · see citing works
Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti–IL-5 antibody SCH55700
Kim, Y., Prussin, C., Martin, B., Law, M. A., Haverty, T. P., Nutman, T. B., & Klion, A. D. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.08.027 · Cited by 113 · see citing works
Interferon-α Treatment of Six Patients with the Idiopathic Hypereosinophilic Syndrome
Butterfield, J. H., & Gleich, G. J. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-9-199411010-00003 · Cited by 111 · see citing works
Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.
Schaller, J. L., & Burkland, G. A. (2001) · PubMed · Cited by 106 · see citing works
Primary restrictive cardiomyopathy. Non-tropical endomyocardial fibrosis and hypereosinophilic heart disease.
Chew, C. Y. C., Ziady, G. M., Raphael, M. J., Nellen, M., & Oakley, C. M. (1977) · Heart · doi:10.1136/hrt.39.4.399 · Cited by 105 · see citing works
[Prognostic factors of hypereosinophilic syndrome. Study of 40 cases].
Lefebvre, C., Blétry, O., Patrice Degoulet, A., Guillevin, L., Bentata-Pessayre, M., Huong, D. U. L. T., & Godeau, P. (1989) · PubMed · Cited by 103 · see citing works
Clonality of Isolated Eosinophils in the Hypereosinophilic Syndrome
Chang, H.-W., Leong, K.-H., Koh, D.-R., & Lee, S. (1999) · Blood · doi:10.1182/blood.v93.5.1651 · Cited by 91 · see citing works
The synergistic influence of human interferon-gamma and interferon-alpha on suppression of hematopoietic progenitor cells is additive with the enhanced sensitivity of these cells to inhibition by interferons at low oxygen tension in vitro.
Broxmeyer, H. E., Cooper, S. H., Rubin, B. Y., & Taylor, M. W. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.4.2502 · Cited by 78 · see citing works
Pharmacokinetics and Pharmacodynamics of SB-240563, a Humanized Monoclonal Antibody Directed to Human Interleukin-5, in Monkeys
Zia‐Amirhosseini, P., Minthorn, E. A., Benincosa, L. J., Hart, T. K., Hottenstein, C. S., Tobia, L. A. P., & Davis, C. B. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35210-3 · Cited by 77 · see citing works
Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis
Bain, B. J. (2004) · American Journal of Hematology · doi:10.1002/ajh.20088 · Cited by 74 · see citing works
Successful non‐myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome
Ueno, N. T., Anagnostopoulos, A., Rondón, G., Champlin, R. E., Mikhailova, N. B., Pankratova, O. S., Zoubarovskaya, L. S., Semenova, E. V., Afanasyev, B. V., O'Brien, S. M., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03771.x · Cited by 67 · see citing works
Invtracardiac thrombi: Frequency, location, etiology, and complications: A morphologvic review—Part V
Waller, B. F., Rohr, T. M., Mclaughlin, T., Grider, L. D., Taliercio, C. P., & Fetters, J. K. (1995) · Clinical Cardiology · doi:10.1002/clc.4960181209 · Cited by 66 · see citing works
Complete Remission of Hypereosinophilic Syndrome after Interferon‐α Therapy: Report of a Case and Literature Review
Yoon, T., Ahn, G., & Chang, S. (2000) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2000.tb02131.x · Cited by 66 · see citing works
Response of six patients with idiopathic hypereosinophilic syndrome to interferon alfa*
Butterfield, J. H., & Gleich, G. J. (1994) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(94)90348-4 · Cited by 63 · see citing works
Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5
Zhang, J., Kuvelkar, R., Murgolo, N., Taremi, S. S., Chou, C., Wang, P., Billah, M. M., & Egan, R. W. (1999) · International Immunology · doi:10.1093/intimm/11.12.1935 · Cited by 56 · see citing works
Mutated interleukin-5 monomers are biologically inactive
McKenzie, A. N. J., Ely, B. K., & Sanderson, C. J. (1991) · Molecular Immunology · doi:10.1016/0161-5890(91)90099-6 · Cited by 48 · see citing works
Aortic and Mitral Valve Replacement in Idiopathic Hypereosinophilic Syndrome
Hendren, W. G., Jones, E. L., & Smith, M. D. (1988) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(10)64701-7 · Cited by 47 · see citing works
Treatment of Hypereosinophilic Syndrome in a Child Using Cyclosporine: Implication for a Primary T-cell Abnormality
Nadarajah, S., Krafchik, B. R., Roifman, C. M., & Horgan-Bell, C. (1997) · PEDIATRICS · doi:10.1542/peds.99.4.630 · Cited by 45 · see citing works
Cytogenetic Studies in Eosinophilic Leukemia
Goh, K.-O., SWISHER, S. N., & ROSENBERG, C. A. (1965) · Annals of Internal Medicine · doi:10.7326/0003-4819-62-1-80 · Cited by 44 · see citing works
Prolonged Clinical Response to Vincristine Treatment in Two Patients with Idiopathic Hypereosinophilic Syndrome
Sakamoto, K. M., Erdreich‐Epstein, A., DeClerck, Y. A., & Coates, T. D. (1992) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199211000-00012 · Cited by 38 · see citing works
Clonal nature of hypereosinophilic syndrome [letter]
Luppi, M., Marasca, R., Morselli, M., Barozzi, P., & Torelli, G. (1994) · Blood · doi:10.1182/blood.v84.1.349.349 · Cited by 35 · see citing works
Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation
Archimbaud, E., Guyotat, D., Guillaume, C., Godard, J., & Fiere, D. M. (1988) · American Journal of Hematology · doi:10.1002/ajh.2830270414 · Cited by 34 · see citing works
Response to Vincristine Treatment in a Case of Idiopathic Hypereosinophilic Syndrome with Multiple Clinical Manifestations
Cofrancesco, E., Cortellaro, M., Pogliani, E., Boschetti, C., Salvatore, M., & Polli, E. O. (2009) · Acta Haematologica · doi:10.1159/000206350 · Cited by 30 · see citing works
Carbamazepine and Fatal Eosinophilic Myocarditis
Salzman, M. B., Valderrama, E., & Sood, S. K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703203361216 · Cited by 30 · see citing works
Idiopathic hypereosinophilic syndrome in a 5½-month-old infant
Wynn, S. R., Sachs, M. I., Keating, M. U., Ostrom, N. K., KADOTA, R. P., O’Connell, E. J., & Smithson, W. A. (1987) · The Journal of Pediatrics · doi:10.1016/s0022-3476(87)80352-9 · Cited by 29 · see citing works
HEREDITARY EOSINOPHILIA: REPORT OF A FAMILY AND REVIEW OF THE LITERATURE.
Jl, N., Oski, F. A., Fh, A., & Lk, D. (1964) · PubMed Central · Cited by 22 · see citing works
Eosinophilic constrictive pericarditis
Virmani, R., Chun, P. K. C., Dunn, B. E., Hartmen, D., & McAllister, H. A. (1984) · American Heart Journal · doi:10.1016/0002-8703(84)90340-5 · Cited by 21 · see citing works
Endomyocardial Disease and Eosinophilia
Felice, P. V., Sawicki, J., & Anto, J. (1993) · Angiology · doi:10.1177/000331979304401104 · Cited by 21 · see citing works
Eosinophilia and granulocytic dysplasia terminating in acute myeloid leukaemia after 24 years
Doorduijn, J. K., van Lom, K., & Löwenberg, B. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.d01-1931.x · Cited by 19 · see citing works
Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?
Tefferi, A., Pardanani, A. D., & Li, C. (2003) · Blood · doi:10.1182/blood-2003-07-2274 · Cited by 17 · see citing works
Unexplained Hypereosinophilia and the Need for Cytogenetic and Molecular Genetic Analyses
Smith, K. J., Jacobson, E. D., Hamza, S. H., & Skelton, H. G. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.5.584 · Cited by 16 · see citing works
Dilated cardiomyopathy in the idiopathic hypereosinophilic syndrome
DePace, N. L., Nestico, P. F., Morganroth, J., Ross, J., Fox, R. M., Kotler, M. N., Mintz, G. S., & Vassallo, R. (1983) · The American Journal of Cardiology · doi:10.1016/0002-9149(83)90605-7 · Cited by 15 · see citing works
Involvement of eosinophils in acute myeloid leukaemia with monosomy 7 demonstrated by fluorescence in situ hybridization
Kwong, Y., & Ha, S. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb05035.x · Cited by 14 · see citing works
MRI findings of muscle involvement in idiopathic hypereosinophilic syndrome
Hundt, W., Stäbler, A., & Reiser, M. F. (1999) · European Radiology · doi:10.1007/s003300050704 · Cited by 11 · see citing works
[Diagnostic and treatment of hypereosinophilia upon return from the tropics: 102 patients].
Molinier, S., Chaudier, B., Kraemer, P., Graffin, B., San, V. V., Imbert, P., Morillon, M., Touze, J. E., & Gras, C. (1998) · PubMed · Cited by 11 · see citing works
Eosinophilia terminating in myeloblastoma
Gershwin, M. E., Fajardo, L. F., Gurwith, M., & Kosek, J. C. (1972) · The American Journal of Medicine · doi:10.1016/0002-9343(72)90178-7 · Cited by 10 · see citing works

Flagged first, then by citations

Sorted by citations

Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes
Valent, P., Klion, A. D., Horny, H., Roufosse, F. E., Gotlib, J. R., Weller, P. F., Hellmann, A. R., Metzgeroth, G., Leiferman, K. M., Arock, M., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.019 · Cited by 766 · see citing works
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Rothenberg, M. E., Klion, A. D., Roufosse, F. E., Kahn, J., Weller, P. F., Simon, H., Schwartz, L. B., Rosenwasser, L. J., Ring, J., Griffin, E. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa070812 · Cited by 583 · see citing works
Self-citation
Quantity and Distribution of Eosinophils in the Gastrointestinal Tract of Children
DEBROSSE, C. W., Case, J. W., Putnam, P. E., Collins, M. H., & Rothenberg, M. E. (2006) · Pediatric and Developmental Pathology · doi:10.2350/11-05-0130.1 · Cited by 277 · see citing works
Self-citation
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works
Hypereosinophilic syndromes
Roufosse, F. E., Goldman, M., & Cogan, E. (2007) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-2-37 · Cited by 170 · see citing works
Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody
Smith, D. A., Minthorn, E. A., & Beerahee, M. (2011) · Clinical Pharmacokinetics · doi:10.2165/11584340-000000000-00000 · Cited by 117 · see citing works
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
Damsky, W., Peterson, D. M., Ramseier, J. Y., Al‐Bawardy, B., Chun, H. J., Proctor, D. D., Strand, V., Flavell, R. A., & King, B. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.10.022 · Cited by 110 · see citing works
Neglected tropical cardiomyopathies: II. Endomyocardial fibrosis
Mocumbi, A. O., Yacoub, S., & Yacoub, M. H. (2008) · Heart · doi:10.1136/hrt.2007.136101 · Cited by 98 · see citing works
The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)–like disease
Yamada, Y., Rothenberg, M. E., Lee, A. W.-T., Akei, H. S., Brandt, E. B., Williams, D. A., & Cancelas, J. A. (2006) · Blood · doi:10.1182/blood-2005-08-3153 · Cited by 84 · see citing works
Self-citation
Do Eosinophil Numbers Differentiate Eosinophilic Esophagitis from Gastroesophageal Reflux Disease?
Genevay, M., Rubbia‐Brandt, L., & Rougemont, A. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.6.815 · Cited by 43 · see citing works
JAK kinases control IL-5 receptor ubiquitination, degradation, and internalization
Martinez-Moczygemba, M., Huston, D. P., & Lei, J. T. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0706465 · Cited by 41 · see citing works
JAK2-Centered Interactome Hotspot Identified by an Integrative Network Algorithm in Acute Stanford Type A Aortic Dissection
Pan, S., Wu, D., Teschendorff, A. E., Hong, T., Wang, L., Qian, M., Wang, C., & Wang, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089406 · Cited by 40 · see citing works
Anti‐Interleukin Therapy in Asthma
Dunn, R., & Wechsler, M. E. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.11 · Cited by 31 · see citing works
Management of Hypereosinophilic Syndrome
Dahabreh, I. J., Giannouli, S., Zoi, C., Zoi, K., Voulgarelis, M., & Moutsopoulos, H. Μ. (2007) · Medicine · doi:10.1097/md.0b013e31815d108c · Cited by 29 · see citing works
Treatment of Hypereosinophilic Syndromes—The First 100 Years
Butterfield, J. H., & Weiler, C. R. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.01.001 · Cited by 24 · see citing works
Current strategies in the management of hypereosinophilic syndrome, including mepolizumab
Schwartz, L. B., Sheikh, J. K., & Singh, A. D. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.493132 · Cited by 19 · see citing works
Oral mucosa lesions in hypereosinophilic syndrome – an update
Ionescu, M., 村田, 秀., & Janin, A. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2007.01393.x · Cited by 13 · see citing works
Erythrodermic cutaneous T cell lymphoma with hypereosinophilic syndrome: Treatment with interferon alfa and extracorporeal photopheresis
Lee, C. H., Mamelak, A. J., & Vonderheid, E. C. (2007) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2007.03190.x · Cited by 13 · see citing works
Challenges in addressing the knowledge gap on endomyocardial fibrosis through community-based studies
Mbanze, J., Cumbane, B., Jive, R., & Mocumbi, A. O. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2019.08.07 · Cited by 12 · see citing works
Chemotactic Factors Associated with Eosinophilic Gastrointestinal Diseases
Blanchard, C., & Rothenberg, M. E. (2009) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2008.10.002 · Cited by 10 · see citing works
Self-citation
Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis
Patel, B., Butterfield, J. H., Weiler, C. R., & Kane, S. V. (2016) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2016.0038 · Cited by 9 · see citing works
Active immunotherapy of allergic asthma with a recombinant human interleukin-5 protein as vaccine in a murine model
Tan, G., Wang, C.-C., Huang, F., Wang, H., Huang, Y., & Lin, Y. (2007) · Chinese Medical Journal · doi:10.1097/00029330-200709010-00010 · Cited by 9 · see citing works
Infliximab as a Therapy for Idiopathic Hypereosinophilic Syndrome
Taverna, J. A. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.9.1110 · Cited by 8 · see citing works
RNA interference against interleukin-5 attenuates airway inflammation and hyperresponsiveness in an asthma model
Chen, S., Huang, F., Tan, G., Wang, C., Huang, Y., Wang, H., Zhou, S., Chen, F., Lin, Y., & Liu, J.-B. (2009) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b0820226 · Cited by 6 · see citing works
Hypereosinophilic Syndrome and Molecularly Targeted Therapy
Martinelli, G., Rondoni, M., Ottaviani, E., Paolini, S., & Baccarani, M. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.02.002 · Cited by 6 · see citing works
Mepolizumab for severe eosinophilic asthma
Kallieri, M., Papaioannou, A. Ι., & Loukides, S. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2545571 · Cited by 5 · see citing works
The Writing on the Wall
Wolpin, B. M., Weller, P. F., Katz, J. T., Levy, B. D., & Loscalzo, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmcps0707685 · Cited by 5 · see citing works
Idiopathic Eosinophilic Pneumonias
Lazor, R., & Cordier, J.-F. (2007) · KARGER eBooks · doi:10.1159/000102694 · Cited by 4 · see citing works
Antisense interleukin-5 reduces eosinophil infiltration and hyperresponsiveness in an allergic asthma model.
Huang, F., Wang, C., Zhou, S., Huang, Y., Wang, H., Chen, F., Lin, Y., Tan, G., & Liu, J.-B. (2009) · PubMed · Cited by 3 · see citing works
Effectiveness of a combination of cyclosporine A, suplatast tosilate and prednisolone on periodic oscillating hypereosinophilia
Imashuku, S., Ueda, & Inaba (2011) · International Medical Case Reports Journal · doi:10.2147/imcrj.s26102 · Cited by 2 · see citing works
Le sindromi ipereosinofile
Civardi, G., Zanlari, L., Bassi, E., Bonassi, R., & Ajolfi, C. (2009) · Italian Journal of Medicine · doi:10.1016/j.itjm.2009.04.001 · Cited by 1 · see citing works
Éosinophilie, syndrome de Churg-Strauss et syndrome hyperéosinophilique
Cogan, E., & Roufosse, F. E. (2007) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2007.09.001 · Cited by 1 · see citing works
Traitement des hyperéosinophilies
Charlanne, H., & Prin, L. (2006) · La Presse Médicale · doi:10.1016/s0755-4982(06)74539-0 · Cited by 1 · see citing works
Invited Commentary
Frankel, S. K., Groshong, S. D., & Lynch, D. A. (2007) · Radiographics · doi:10.1148/radiographics.27.3.0270637 · Cited by 1 · see citing works
Management of F/P+/− Hypereosinophilic Syndromes
Kalra, A., Palaniswamy, C., Kalra, A., Wig, N., & Sood, R. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181ee7370
Peripheral Eosinophilia and Diagnosis of Hypereosinophilic Syndrome
Sims, K. L. (2006) · Laboratory Medicine · doi:10.1309/rk23-4qmg-lx0j-pg0e
IL-5-directed approaches in the treatment of eosinophil-driven disease
Marshall, R. P., & Faiferman, I. (2010) · Progress in respiratory research/Progress in research in emphysema and chronic bronchitis/Progress in respiration research · doi:10.1159/000320806
Characterization and antagonism of cytokine-induced eosinophil priming
Rosas, R., & Marcela, A. (2006) · Utrecht University Repository (Utrecht University)
The influence of PAR activators on allergen-induced pulmonary eosinophilia and hyperresponsiveness in mice
CAMPO, B. A. D. (2007) · UWA Profiles and Research Repository (UWA)
Hypereosinophilic syndromes
Civardi, G., Zanlari, L., Bassi, E., Bonassi, R., & Ajolfi, C. (2013) · Italian Journal of Medicine · doi:10.4081/itjm.2009.129

Hypereosinophilic syndromes and new therapeutic approaches including anti-IL-5
Stein, M., & Rothenberg, M. E. (2005) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.1.4.633 · Cited by 3 · see citing works
Self-citation
Hypereosinophilic syndromes: A novel therapeutic indication for tyrosine kinase inhibitors and IL-5 antagonists
Roufosse, F. E., Goldman, M., & Cogan, E. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.02.010
Anti–interleukin-5 therapy for asthma and hypereosinophilic syndrome
Kay, A. B., & Klion, A. D. (2004) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2004.06.007 · Cited by 47 · see citing works
Efficacy of anti-interleukin 5 therapy in hypereosinophilic syndrome: An updated systematic review and meta-analysis
Masood, S., Paracha, M. R., Ahmed, S., Malik, M., Khalid, A. R., Khalid, M. H., Fatima, L., Nasir, B. M., Rahman, S. U., Khan, K., et al. (2025) · Allergy and Asthma Proceedings · doi:10.2500/aap.2025.46.240106 · Cited by 3 · see citing works
Diagnosis and treatment of hypereosinophilic syndromes
Fletcher, S. H., & Bain, B. J. (2007) · Current Opinion in Hematology · doi:10.1097/00062752-200701000-00008 · Cited by 55 · see citing works

Authors: SUTTON, S., ASSAAD, A., & ROTHENBERG, M.
Affiliations: Cincinnati Children's Hospital Medical Center (US)
Corresponding author: ROTHENBERG, M
ORCID: ROTHENBERG, M
Venue: Clinical Immunology
Publisher: Elsevier BV
Published: 2005-04
Volume: 115
Issue: 1
Pages: 51-60
ISSN: 1521-6616 (ISSN-L)
DOI: 10.1016/j.clim.2005.02.006
OpenAlex: W2041887944
Cited by: 40
References: 67
Citations by year: 2025: 1 · 2020: 3 · 2016: 1 · 2014: 2 · 2013: 1 · 2012: 2
FWCI: 3.86
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Clinical Immunology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords: hypereosinophilic syndrome, IL-5, anti-IL-5 therapy, humanized monoclonal antibody, eosinophilia, tyrosine kinase, eosinophil activation
MeSH terms: Imatinib Mesylate, Adult, Antibodies, Monoclonal, Benzamides, Female, Humans, Male, Middle Aged, Piperazines, Pyrimidines, Interleukin-5, Hypereosinophilic Syndrome, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Anti-IL-5 and hypereosinophilic syndromes

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks